FindTrial
Sign In

Fungal infections after antifungal agent posaconazole prophylaxis in transplant patients

Breakthrough IFIs after posaconazole prophylaxis in allogeneic BMT patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/05/014177
Enrollment
50
Registered
2018-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Allogeneic bone marrow transplant and on posaconazole prophylaxis

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Rajiv Gandhi Cancer Institute and Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergone allogeneic bone marrow transplant and on posaconazole prophylaxis between 1st January 2015 to 31st December 2017

Exclusion criteria

Exclusion criteria: Patients previously treated with antifungal therapy for invasive fungal infections anytime before transplant

Design outcomes

Primary

MeasureTime frame
Use of posaconazole prophylaxis in allogeneic bone marrow transplant patients and reduce mortality due to fungal infectionsTimepoint: Outcome will be analysed on completion of three years from the date of transplant of first patient.—

Secondary

MeasureTime frame
To identify risk factors using univariate and multivariate analysisTimepoint: Outcome will be analysed on completion of three years from the date of transplant of first patient.—

Countries

India

Contacts

Public ContactSanghmitra

Rajiv Gandhi Cancer Institute and Research Centre

iamsamy.st@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026